Adefovir — Membership Pricing

Other medications in Infections

• Atazanavir
• Aztreonam
• Baloxavir
• Bictegravir
• Cefaclor
• Cefadroxil
• Cefdinir
• Cefixime

About Adefovir

Adefovir, an important antiviral medication, plays a crucial role in managing chronic Hepatitis B infection, helping to slow disease progression and improve liver health. If you or a loved one rely on this vital treatment, understanding its impact and cost is essential. TheDrugClub is dedicated to making necessary medications like adefovir more accessible and affordable for our members, ensuring you can focus on your health without undue financial stress.

Adefovir is primarily prescribed for the treatment of chronic Hepatitis B virus (HBV) infection in adults. This persistent viral infection can lead to serious liver damage, including cirrhosis and liver cancer, if left untreated. By targeting the virus, adefovir helps to reduce viral load, minimize liver inflammation, and prevent further disease progression. It

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Adefovir is approved for (FDA label)

Adefovir dipivoxil tablets are indicated for the treatment of chronic hepatitis B in patients 12 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. This indication is based on histological, virological, biochemical, and serological responses in adult patients with HBeAg+ and HBeAg- chronic hepatitis B with compensated liver function, and with clinical evidence of lamivudine-resistant hepatitis B virus with either compensated or decompensated liver function. For patients 12 to less than 18 years of age, the indication is based on virological and biochemical responses in patients with HBeAg+ chronic hepatitis B virus infection with compensated liver function.

Source: Read the full FDA label on DailyMed. Label effective date: July 22, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Adefovir (FDA label)

WARNING: SEVERE ACUTE EXACERBATIONS OF HEPATITIS, NEPHROTOXICITY, HIV RESISTANCE, LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY WITH STEATOSIS Severe acute exacerbations of hepatitis have been reported in patients who have discontinued anti-Hepatitis B therapy including adefovir dipivoxil tablets. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-Hepatitis B therapy. If appropriate, resumption of anti-Hepatitis B therapy may be warranted [See Warnings and Precautions (5. 1 ) ]. In patients at risk of or having underlying renal dysfunction, chronic administration of adefovir dipivoxil tablets may result in nephrotoxicity.

Source: FDA prescribing information (DailyMed). Set ID: 08e07fae-3191-b6a3-c894-d3a8cc53923f. SPL document ID: bd0233d0-e141-a321-66a5-4afd09dbabfe. Label effective date: July 22, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Adefovir (FDA label)

Adefovir Dipivoxil Tablets are white to off-white, round, flat-faced bevelled edge tablets, engraved “APO” on one side, “A10” on the other side. Tablets: 10 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 08e07fae-3191-b6a3-c894-d3a8cc53923f. SPL document ID: bd0233d0-e141-a321-66a5-4afd09dbabfe. Label effective date: July 22, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Adefovir (FDA label)

The following adverse reactions are discussed in other sections of the labeling: Severe acute exacerbations of Hepatitis [ S ee Boxed Warning , Warnings and Precautions (5.1) ] Nephrotoxicity [See Boxed Warning , Warnings and Precautions (5.2) ] Most common adverse reaction (incidence greater than 5%) in compensated liver disease patients were asthenia, headache, abdominal pain and nausea. ( 6.1 ) The most common adverse reaction in pre- and post- transplantation lamivudine-resistant liver disease patients was increased creatinine. ( 6.2 ) To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp. at 1-800-706-5575or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 08e07fae-3191-b6a3-c894-d3a8cc53923f. SPL document ID: bd0233d0-e141-a321-66a5-4afd09dbabfe. Label effective date: July 22, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Adefovir (FDA label)

Adefovir dipivoxil tablets are contraindicated in patients with previously demonstrated hypersensitivity to any of the components of the product. Adefovir dipivoxil tablets are contraindicated in patients with previously demonstrated hypersensitivity to any of the components of the product. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 08e07fae-3191-b6a3-c894-d3a8cc53923f. SPL document ID: bd0233d0-e141-a321-66a5-4afd09dbabfe. Label effective date: July 22, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Adefovir (FDA label)

Severe acute exacerbations of hepatitis: Monitor hepatic function closely at repeated intervals for at least several months in patients who discontinue adefovir dipivoxil. ( 5.1 ) Nephrotoxicity: Monitor renal function during therapy for all patients, particularly those with pre-existing or other risks for renal impairment. Dose adjustment may be required. ( 5.2 ) HIV Resistance: Offer HIV testing to all patients prior to initiating adefovir dipivoxil. Untreated HIV may result in HIV resistance. ( 5.3 ) Lactic acidosis and severe hepatomegaly with steatosis: If suspected, suspend treatment. ( 5.4 ) Coadministration with Other Products: Do not administer adefovir dipivoxil concurrently with VIREAD ® or other tenofovir-containing products. ( 5.5 ) Clinical Resistance: For patients with lamivudine-resistant HBV use adefovir dipivoxil in combination with lamivudine.

Source: FDA prescribing information (DailyMed). Set ID: 08e07fae-3191-b6a3-c894-d3a8cc53923f. SPL document ID: bd0233d0-e141-a321-66a5-4afd09dbabfe. Label effective date: July 22, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Adefovir (FDA label)

Since adefovir is eliminated by the kidney, coadministration of adefovir dipivoxil with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either adefovir and/or these coadministered drugs [See Clinical Pharmacology ( 12.3) ]. Patients should be monitored closely for adverse events when adefovir dipivoxil is coadministered with drugs that are excreted renally or with other drugs known to affect renal function [ See Warnings and Precautions (5.2) ] . Adefovir dipivoxil should not be administered in combination with VIREAD [ See Warnings and Precautions (5.5)] . Coadministration with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of adefovir or the coadministered drug. Monitor for adefovir dipivoxil associated adverse events. ( 7 )

Source: FDA prescribing information (DailyMed). Set ID: 08e07fae-3191-b6a3-c894-d3a8cc53923f. SPL document ID: bd0233d0-e141-a321-66a5-4afd09dbabfe. Label effective date: July 22, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.